ASCO: AstraZeneca's Enhertu Is Poised To Change The Breast Cancer Paradigm
Executive Summary
The results of DESTINY-Breast04 could impact survival for approximately 50% of patients diagnosed with metastatic breast cancer today, principal investigator Modi said at the American Society of Clinical Oncology annual meeting.
You may also be interested in...
AstraZeneca/Daiichi Sankyo Line Up More Enhertu Indications
The high-profile antibody-drug conjugate has shown its potential to improve outcomes for heavily pre-treated patients in diseases such as bladder, cervical, pancreatic and rare cancers in a mid-stage trial.
New Deals, Modalities In Sights In Japan After Relatively Quiet 2022
After a comparatively subdued 2022 in terms of M&A and other deal-making, a strengthening currency and interest in new areas such as digital tools and cell and gene therapy might see a rebound in activity this year, which should also see domestic approvals of several potential blockbusters and more support for bioventures.
New Deals, Modalities In Sights In Japan After Relatively Quiet 2022
After a comparatively subdued 2022 in terms of M&A and other deal-making, a strengthening currency and interest in new areas such as digital tools and cell and gene therapy might see a rebound in activity this year, which should also see domestic approvals of several potential blockbusters and more support for bioventures.